OPK

MKT CAP:$944M

OPKO Health, Inc.

Market Cap

$944M

Healthcare·Medical - Diagnostics & Research·🇺🇸 United States·NASDAQ

Healthcare·Medical·🇺🇸·NASDAQ

Stock Price

$1.22-$0.05 (-3.94%)

Apr 21, 2026

Company Details

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Lab...

CEO

Phillip Frost

IPO Date

Nov 2, 1995

Website

www.opko.com

Key Metrics TTM

Revenue

$607M

-14.9% YoY

Net Income

-$226M

EPS (Diluted)

-$0.33

Free Cash Flow

-$191M

Revenue / Share

$0.79

Gross Margin

41.5%

Operating Margin

-19.3%

Net Margin

-37.2%

FCF Margin

-31.4%

P/S

1.6x

P/E

—

Earnings Reports

Q1 2026

Apr 29, 2026

PENDING

FY 2025

Feb 26, 2026

$607M-14.9%EPS -$0.30

Q4 2025

Feb 26, 2026

$149M-19.1%EPS -$0.04

Q3 2025

Oct 29, 2025

$152M-12.6%EPS $0.03

Q2 2025

Jul 31, 2025

$157M-13.9%EPS -$0.22

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q1 22	$329M	$85M	-$72M
Q2 22	$310M	$116M	-$11M
Q3 22	$180M	$31M	-$88M
Q4 22	$185M	$56M	-$55M
Q1 23	$238M	$99M	-$31M
Q2 23	$265M	$126M	$7M
Q3 23	$179M	$48M	-$64M
Q4 23	$182M	$45M	-$69M
Q1 24	$174M	$42M	-$71M
Q2 24	$182M	$52M	-$62M
Q3 24	$174M	$40M	$14M
Q4 24	$184M	$85M	-$33M
Q1 25	$150M	$43M	-$67M
Q2 25	$157M	$49M	-$60M
Q3 25	$152M	$71M	$48M
Q4 25	$149M	$89M	-$38M

Valuation

Quarter	P/S	P/E
Q1 22	1.5x	—
Q2 22	1.3x	—
Q3 22	1.2x	—
Q4 22	0.9x	—
Q1 23	1.3x	—
Q2 23	1.8x	—
Q3 23	1.3x	—
Q4 23	0.8x	—
Q1 24	1.2x	—
Q2 24	1.2x	—
Q3 24	1.5x	—
Q4 24	1.4x	—
Q1 25	1.7x	—
Q2 25	1.3x	—
Q3 25	1.5x	—
Q4 25	1.7x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 22	-$20M	-$25M
Q2 22	-$11M	-$17M
Q3 22	-$32M	-$40M
Q4 22	-$32M	-$38M
Q1 23	-$23M	-$26M
Q2 23	-$365.0K	-$6M
Q3 23	$33M	$29M
Q4 23	-$38M	-$41M
Q1 24	-$36M	-$40M
Q2 24	-$26M	-$34M
Q3 24	-$77M	-$85M
Q4 24	-$44M	-$50M
Q1 25	-$35M	-$38M
Q2 25	-$83M	-$87M
Q3 25	-$35M	-$38M
Q4 25	-$26M	-$29M

Capital Expenditures

Quarter	CapEx
Q1 22	$5M
Q2 22	$5M
Q3 22	$8M
Q4 22	$6M
Q1 23	$3M
Q2 23	$6M
Q3 23	$4M
Q4 23	$3M
Q1 24	$4M
Q2 24	$7M
Q3 24	$8M
Q4 24	$5M
Q1 25	$3M
Q2 25	$3M
Q3 25	$3M
Q4 25	$3M

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 22	-39.6%	-20.7%
Q2 22	-30.0%	-26.6%
Q3 22	-53.4%	-23.1%
Q4 22	-53.8%	-48.2%
Q1 23	-27.8%	-33.2%
Q2 23	-14.4%	-19.4%
Q3 23	-0.6%	-9.2%
Q4 23	-1.9%	+4.3%
Q1 24	-26.9%	-8.6%
Q2 24	-31.4%	-5.6%
Q3 24	-2.8%	-34.4%
Q4 24	+1.0%	-13.6%
Q1 25	-13.7%	-11.4%
Q2 25	-13.9%	-11.1%
Q3 25	-12.6%	-35.0%
Q4 25	-19.1%	-13.8%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 22	$8M	2.3%
Q2 22	$4M	1.4%
Q3 22	$3M	1.9%
Q4 22	$3M	1.7%
Q1 23	$3M	1.1%
Q2 23	$3M	1.1%
Q3 23	$3M	1.8%
Q4 23	$3M	1.5%
Q1 24	$3M	1.5%
Q2 24	$3M	1.4%
Q3 24	$3M	1.6%
Q4 24	$3M	1.7%
Q1 25	$3M	1.7%
Q2 25	$2M	1.4%
Q3 25	$3M	2.0%
Q4 25	$3M	2.0%

OpEx Breakdown

Quarter	R&D	SG&A
Q1 22	$18M	$118M
Q2 22	$17M	$101M
Q3 22	$19M	$80M
Q4 22	$20M	$74M
Q1 23	$33M	$76M
Q2 23	$18M	$80M
Q3 23	$19M	$72M
Q4 23	$19M	$73M
Q1 24	$22M	$70M
Q2 24	$24M	$69M
Q3 24	$29M	$98M
Q4 24	$30M	$67M
Q1 25	$31M	$59M
Q2 25	$30M	$60M
Q3 25	$30M	$54M
Q4 25	$33M	$51M

Revenue Segments

Quarter	Product	Service	Transfer of Intellectual Property and Other
Q1 22	$37M	$287M	$6M
Q2 22	$36M	$187M	$87M
Q3 22	$32M	$143M	$5M
Q4 22	$38M	$139M	$8M
Q1 23	$40M	$132M	$65M
Q2 23	$44M	$127M	$95M
Q3 23	$41M	$132M	$6M
Q4 23	$43M	$124M	$15M
Q1 24	$38M	$127M	$9M
Q2 24	$40M	$129M	$12M
Q3 24	$39M	$121M	$13M
Q4 24	$37M	$103M	$43M
Q1 25	$35M	$103M	$12M
Q2 25	$41M	$101M	$15M
Q3 25	$38M	$95M	$19M
Q4 25	$44M	$71M	$34M

Revenue by Geography

Quarter	Chile	Ireland	Israel	Mexico	Other Countries	Spain	United States
Q1 22	$16M	$8M	$2M	$4M	$193.0K	$7M	$292M
Q2 22	$16M	$89M	$2M	$4M	$202.0K	$6M	$193M
Q3 22	$14M	$7M	$251.0K	$4M	$174.0K	$5M	$150M
Q4 22	$16M	$13M	$182.0K	$3M	$294.0K	$5M	$148M
Q1 23	$16M	$16M	$5M	$6M	$575.0K	$6M	$189M
Q2 23	$20M	$97M	$2M	$6M	$525.0K	$6M	$135M
Q3 23	$17M	$9M	$3M	$6M	$565.0K	$4M	$139M
Q4 23	$16M	$20M	$350.0K	$3M	$581.0K	$7M	$135M
Q1 24	$15M	$9M	$160.0K	$7M	$630.0K	$6M	$136M
Q2 24	$18M	$10M	$441.0K	$6M	$804.0K	$6M	$142M
Q3 24	$17M	$12M	$196.0K	$6M	$756.0K	$6M	$133M
Q4 24	$16M	$18M	$975.0K	$5M	$933.0K	$7M	$136M
Q1 25	$15M	$5M	$73.0K	$6M	$992.0K	$6M	$116M
Q2 25	$16M	$12M	$139.0K	$6M	$1M	$7M	$115M
Q3 25	$14M	$12M	$140.0K	$7M	$1M	$6M	$111M
Q4 25	$17M	$22M	$170.0K	$6M	$1M	$7M	$94M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$102M	$0	$102M
Q2 22	$210M	$0	$210M
Q3 22	$181M	$0	$181M
Q4 22	$153M	$0	$153M
Q1 23	$111M	$0	$111M
Q2 23	$108M	$0	$108M
Q3 23	$139M	$0	$139M
Q4 23	$96M	$0	$96M
Q1 24	$76M	$0	$76M
Q2 24	$41M	$0	$41M
Q3 24	$406M	$0	$406M
Q4 24	$432M	$0	$432M
Q1 25	$436M	$0	$436M
Q2 25	$272M	$0	$272M
Q3 25	$415M	$0	$415M
Q4 25	$369M	$0	$369M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q1 22	660M	+1.3%	+3.0%
Q2 22	713M	+7.9%	+10.1%
Q3 22	750M	+5.3%	+15.1%
Q4 22	750M	-0.0%	+15.1%
Q1 23	752M	+0.2%	+13.8%
Q2 23	752M	+0.0%	+5.5%
Q3 23	752M	-0.0%	+0.2%
Q4 23	752M	-0.0%	+0.2%
Q1 24	707M	-5.9%	-5.9%
Q2 24	697M	-1.4%	-7.3%
Q3 24	696M	-0.2%	-7.4%
Q4 24	694M	-0.2%	-7.6%
Q1 25	672M	-3.2%	-5.0%
Q2 25	672M	0.0%	-3.7%
Q3 25	780M	+16.1%	+12.1%
Q4 25	766M	-1.8%	+10.3%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q1 22	$57.1K	6K
Q2 22	$53.7K	6K
Q3 22	$31.2K	6K
Q4 22	$44.2K	4K
Q1 23	$56.6K	4K
Q2 23	$63.3K	4K
Q3 23	$42.6K	4K
Q4 23	$46.3K	4K
Q1 24	$44.2K	4K
Q2 24	$46.4K	4K
Q3 24	$44.2K	4K
Q4 24	$61.3K	3K
Q1 25	$50.0K	3K
Q2 25	$52.3K	3K
Q3 25	$50.6K	3K
Q4 25	$65.3K	2K

Revenue / Employee